Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Clivatuzumab-MMAE (ADC) (DHD14297)

Applications:Research Grade Biosimilar
Overview

Catalog No.

DHD14297

Description

Clivatuzumab-MMAE is an ADC consisting of a MUC1-directed antibody and Monomethyl auristatin E (MMAE) used for the study of pancreatic cancer.

Species reactivity

Human

Clonality

Monoclonal

Target

PEMT, CA 15-3, H23AG, Peanut-reactive urinary mucin, PEM, EMA, Cancer antigen 15-3, MUC-1, Episialin, MUC1-CT, MUC1-beta, Tumor-associated mucin, CD227, Polymorphic epithelial mucin, KL-6, MUC1-alpha, MUC1, PUM, Krebs von den Lungen-6, MUC1-NT, Tumor-associated epithelial membrane antigen, Mucin-1, Breast carcinoma-associated antigen DF3, Carcinoma-associated mucin

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SEC.

Purification

Purified by Ion Exchange Chromatography.

Applications

Research Grade Biosimilar

Form

Liquid

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Clivatuzumab-MMAE

Data Image
References
Datasheet

Document Download

Clivatuzumab-MMAE (ADC).pdf

 

$ 2540
Product specifications
1 mg 2540 5 mg 6360

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Clivatuzumab-MMAE (ADC) [DHD14297]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only